MarketVue®: Chronic Refractory Gout
The MarketVue®: Chronic Refractory Gout market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Chronic Refractory Gout report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 20 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• LG Chem
• Jiangsu Hengrui Pharmaceuticals
• JW Group/Simcere
• Selecta / Cartesian Therapeutics
• Sobi Biosciences
• Teijin America
• InventisBio
• Arthrosi Therapeutics
• Shanton Pharma
• Atom Bioscience
• Horizon Therapeutics / Amgen
• Nippon Chemiphar
• Protalix BioTherapeutics
• Arrowhead Pharmaceuticals
• Hinova Pharmaceuticals
Key drugs mentioned:
• Colchicine (Colcrys, Mitigare)
• Allopurinol (Zyloprim)
• Febuxostat (Uloric)
• Probenecid (Probalan)
• Pegloticase (Krystexxa)
• Tigulixostat / LC350189
• Ruzinurad / SHR4640
• Epaminurad / URC102
• SEL-212
• TMX-049
• D-0120
• AR882
• SAP-001
• ABP-671
• HZN-003
• HZN-007
• NC-2500
• PRX-115
• HZN-457
• HP501
Please note: the online download version of this report is for a global site license.
- 1. DISEASE OVERVIEW
- A treatment-resistant inflammatory arthritis causing flares of severe joint pain and inflammation
- Figure 1.1. Gout pathophysiology
- Numerous risk factors for severe gout, but few truly refractory cases
- Table 1.1 Gout risk factors
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease Definition
- Figure 2.1. G6 diagnosed prevalent cases of refractory gout by region
- Table 2.1 Diagnosed prevalent populations of gout and refractory gout in the U.S. and EU5
- Annualized incidence
- Figure 2.2. Amgen/Horizon uncontrolled gout epidemiology funnel for U.S.
- Table 2.2. Diagnosed annualized incident cases of gout and refractory gout in the U.S. and EU5
- 3. DIAGNOSIS & CURRENT TREATMENT
- Overview
- Figure 3.1. Referral and diagnostic pathway for gout patients
- The vast majority of patients achieve flare control with available treatment options
- Table 3.1. Treatment goals for chronic refractory gout
- Table 3.2. Types of urate lowering therapies
- Treatment flow for gout
- Figure 3.2. Treatment algorithm for gout
- Krystexxa (pegloticase)
- Figure 3.3. Krystexxa safety and efficacy w/ and w/o methotrexate
- Physician perspectives on Krystexxa
- Figure 3.4. Pegloticase – upsides and downsides
- Figure 3.5 Surveyed rheumatologist-estimated Krystexxa share and discontinuation rate
- Physician perspectives on Krystexxa (cont)
- Key treatment dynamics that will shape disease management and drug use in gout
- Table 3.3 Must-know treatment dynamics in chronic refractory gout
- Improved uricase and uricosuric formulations may vastly change the gout treatment landscape
- Figure 3.6. Important dynamics of chronic refractory gout market evolution
- 4. UNMET NEED
- Overview
- Figure 4.1. Top unmet needs in chronic refractory gout
- Physician perspectives on unmet needs in chronic refractory gout
- 5. PIPELINE ANALYSIS
- Overview
- Table 5.1. Urate lowering therapies in late-stage development
- Results from Sobi and Selecta’s Phase III trial of SEL-212 uricase therapy rivals Krystexxa with methotrexate
- Figure 5.1. SEL-212 Phase 3 safety and efficacy
- Uricosuric agents dominate the late-stage pipeline, but there are novel uricases in early development
- Table 5.2. Urate lowering therapies in early-stage development
- 6. VALUE & ACCESS
- Overview
- Table 6.1. Current pricing of gout therapies, U.S.
- Table 6.2. Typical U.S. commercial payer prior authorization criteria for Krystexxa
- Payer financial burden of chronic refractory gout
- Figure 6.1. Mean annual healthcare costs per patient by healthcare resource for refractory gout
- Horizon has developed a number of programs to increase access and affordability of Krystexxa
- 7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook